AN2 Therapeutics, Inc. (ANTX)
| Market Cap | 247.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.72M |
| Shares Out | 19.40M |
| EPS (ttm) | -1.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,156 |
| Open | 18.79 |
| Previous Close | 18.43 |
| Day's Range | 12.42 - 20.29 |
| 52-Week Range | 12.46 - 23.58 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 25.16 (+97.5%) |
| Earnings Date | n/a |
About ANTX
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Its novel mechanism of action is enabled by boron chemistry, our core technology approach. W...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is 25.16, which is an increase of 97.49% from the latest price.
News
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious inf...
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high ...
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million. The Company announced IPO plans earl...
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious disea...